(Q26781809)

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Polyacrylamide gel for facial wasting rehabilitation: how many milliliters per session?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and submalar silicone implants

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Experience in the treatment of HIV-associated lipodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Objective evidence for the use of polylactic acid implants in HIV-associated facial lipoatrophy using three-dimensional surface laser scanning and psychological assessment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Early and late complications of polyalkylimide gel (Bio-Alcamid)®

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Patient satisfaction following Bio-Alcamid injection for facial contour defects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Does severity predict distress? The relationship between subjective and objective measures of appearance and psychological adjustment, during treatment for facial lipoatrophy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Non-hyaluronic acid fillers

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

HIV-associated facial lipoatrophy treated with injectable silicone oil: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

The face of HIV and AIDS: can we erase the stigma?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Cost consequences of HIV-associated lipoatrophy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Long-Term Psychometric Outcomes of Facial Lipoatrophy Therapy: Forty-Eight–Week Observational, Nonrandomized Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

5-year study of a polyacrylamide hydrogel-based filler for rehabilitation of HIV-related facial lipoatrophy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Relationship between HAART adherence and adipose tissue alterations

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: a 2-year clinical experience.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Long-term efficacy and safety of polyacrylamide hydrogel injection in the treatment of human immunodeficiency virus-related facial lipoatrophy: a 5-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Cheek augmentation with Bio-Alcamid in facial lipoatrophy in HIV seropositive patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Safety and efficacy of one-step rehabilitation of human immunodeficiency virus-related facial lipoatrophy using an injectable calcium hydroxylapatite dermal filler

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Lipoatrophy in patients with AIDS: treatment with polymethylmethacrylate in Amazonas, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

An index for staging facial lipoatrophy and evaluation of the efficacy of the treatment with polymethylmethacrylate in HIV/AIDS patients: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Polymethylmethacrylate facial implant: a successful personal experience in Brazil for more than 9 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Complications after treatment with polyalkylimide

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Polyacrylamide gel injection for treatment of human immunodeficiency virus-associated facial lipoatrophy: 18 months follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Four-year follow-up of polyalkylimide gel use for the treatment of HIV-associated lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021

Treatment of HIV-associated facial lipoatrophy: impact on infection progression assessed by viral load and CD4 count

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2015.08.040

7 January 2021